

10/731,607

=> file caplus

FILE 'CAPLUS' ENTERED AT 14:41:54 ON 21 JUN 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Jun 2005 VOL 142 ISS 26

FILE LAST UPDATED: 20 Jun 2005 (20050620/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l4 ibib abs hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:193931 CAPLUS

DOCUMENT NUMBER: 130:252356

TITLE: Preparation of 2-[(arylmethyl)phenylamino]-2-imidazolines as prostaglandin IP receptor antagonists
INVENTOR(S): Bley, Keith Roger; Clark, Robin Douglas; Jahangir, Alam; Kowalczyk, Bruce Andrew; Lopez-Tapala, Francisco Javier; Muehldorf, Alexander Victor; O'Yang, Counde; Sun, Thomas Weitao

PATENT ASSIGNEE(S): F. Hoffmann-La Roche AG, Switz.

SOURCE: Eur. Pat. Appl., 61 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 902018	A2	19990317	EP 1998-116091	19980826
EP 902018	A3	20010502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NZ 331480	A	20000228	NZ 1998-331480	19980820
US 6184242	B1	20010206	US 1998-137507	19980820
CA 2245755	AA	19990304	CA 1998-2245755	19980827
IL 125982	A1	20020912	IL 1998-125982	19980828
ZA 9807925	A	19990304	ZA 1998-7925	19980831
JP 11140057	A2	19990525	JP 1998-248047	19980902
JP 3040752	B2	20000515		
NO 9804044	A	19990305	NO 1998-4044	19980903
NO 312294	B1	20020422		
AU 9883094	A1	19990318	AU 1998-83094	19980903
AU 746480	B2	20020502		
BR 9803373	A	20010424	BR 1998-3373	19980903

10/731,607

RU 2211834	C2	20030910	RU 1998-117245	19980903
CN 1216762	A	19990519	CN 1998-118587	19980904
CN 1110484	B	20030604		
TW 432046	B	20010501	TW 1998-87114724	19980908
HK 1019334	A1	20040213	HK 1999-104374	19991007
US 6472536	B1	20021029	US 2000-666065	20000919
US 2003036655	A1	20030220	US 2002-159589	20020531
US 6596876	B2	20030722		
US 2003229123	A1	20031211	US 2003-425778	20030429
US 6693200	B2	20040217		
US 2004122053	A1	20040624	US 2003-731607	20031209

PRIORITY APPLN. INFO.:

US 1997-57808P	P	19970904
US 1998-89916P	P	19980619
US 1998-88015P	P	19980604
US 1998-137507	A3	19980820
US 2000-666065	B3	20000919
US 2002-159589	A3	20020531
US 2003-425778	A3	20030429

OTHER SOURCE(S): MARPAT 130:252356


AB R1CH2ZNHR (R = 2-imidazolin-2-yl) [I; R1 = R3Z1, R5Z2, (un)substituted 4-piperidiny, etc.; R3 = halo, (cyclo)alkyl, heterocyclyl, (di) (alkyl) amino, carbamoyl (alkyl), etc.; R5 = hydroxy (alkyl), alkoxy (alkyl), acylalkoxy, etc.; Z, Z1 = (un)substituted 1,4-phenylene; Z2 = pyrrole-, furan-, or thiophene-3-, -4-, or -5,2-diyl] were prepared as prostaglandin IP receptor antagonists (no data). Thus, PhOMe was acylated by 4-(O2N)C6H4COCl and the product treated with HBr to give 4-(HO)C6H4COC6H4(NO2)-4 which was etherified by Me2CBr and the reduced product condensed with 2-chloro-2-imidazoline to give I [R1 = 4-(Me2CO)C6H4, Z = 1,4-phenylene].

IT 221531-76-6P 221531-77-7P 221531-78-8P
221531-79-9P 221531-80-2P 221531-81-3P
221531-82-4P 221531-84-6P 221531-85-7P
221531-86-8P 221533-09-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-[(arylmethyl)phenylamino]-2-imidazolines as prostaglandin IP receptor antagonists)

RN 221531-76-6 CAPLUS


CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 221531-77-7 CAPLUS


CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

10/731,607




● HCl

RN 221531-78-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 221531-79-9 CAPLUS
CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 221531-80-2 CAPLUS
CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 221531-81-3 CAPLUS
CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-


10/731,607

[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 221531-82-4 CAPLUS

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 221531-84-6 CAPLUS

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(3-methyl-1-oxobutyl)- (9CI) (CA INDEX NAME)



RN 221531-85-7 CAPLUS

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(4-methyl-1-oxopentyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 221531-86-8 CAPLUS


CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(1-pyrrolidinylsulfonyl)- (9CI) (CA INDEX NAME)

10/731,607



RN 221533-09-1 CAPLUS

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(1-piperidinylsulfonyl)- (9CI) (CA INDEX NAME)



=> => file uspatall

FILE 'USPATFULL' ENTERED AT 14:42:39 ON 21 JUN 2005


CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:42:39 ON 21 JUN 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> d que

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 15 SEA FILE=REGISTRY SSS FUL L1

L6 8 SEA L3

=> d 16 1-8 ibib abs hitstr

L6 ANSWER 1 OF 8 USPATFULL on STN

10/731,607

ACCESSION NUMBER: 2004:159249 USPATFULL
TITLE: 2-(substituted-phenyl)amino-imidazoline derivatives
INVENTOR(S): Bley, Keith Roger, Mountain View, CA, UNITED STATES
Clark, Robin Douglas, Palo Alto, CA, UNITED STATES
Jahangir, Alam, San Jose, CA, UNITED STATES
Kowalczyk, Bruce Andrew, Redwood City, CA, UNITED STATES
Lopez-Tapia, Francisco Javier, Fremont, CA, UNITED STATES
Muehldorf, Alexander Victor, Sunnyvale, CA, UNITED STATES
O'Yang, Counde, Sunnyvale, CA, UNITED STATES
Sun, Thomas Weitao, Fremont, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004122053	A1	20040624
APPLICATION INFO.:	US 2003-731607	A1	20031209 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2003-425778, filed on 29 Apr 2003, GRANTED, Pat. No. US 6693200 Division of Ser. No. US 2002-159589, filed on 31 May 2002, GRANTED, Pat. No. US 6596876 Division of Ser. No. US 2000-666065, filed on 19 Sep 2000, GRANTED, Pat. No. US 6472536 Division of Ser. No. US 1998-137507, filed on 20 Aug 1998, GRANTED, Pat. No. US 6184242		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-89916P	19980619 (60)
	US 1998-88015P	19980604 (60)
	US 1997-57808P	19970904 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROCHE PALO ALTO LLC, PATENT LAW DEPT. M/S A2-250, 3431 HILLVIEW AVENUE, PALO ALTO, CA, 94304	
NUMBER OF CLAIMS:	65	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	3488	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to IP receptor antagonists selected from the group of compounds represented by Formula I: ##STR1##

where:


R.sup.1 is a group represented by formula (A), (B) or (C); ##STR2##

and other substituents as defined in the specification, and their pharmaceutically acceptable salts or crystal forms thereof; and pharmaceutical compositions containing them; and methods for their use as therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 221531-76-6P 221531-77-7P 221531-78-8P
221531-79-9P 221531-80-2P 221531-81-3P
221531-82-4P 221531-84-6P 221531-85-7P
221531-86-8P 221533-09-1P
(preparation of 2-[(arylmethyl)phenylamino]-2-imidazolines as prostaglandin IP receptor antagonists)
RN 221531-76-6 USPATFULL
CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

10/731,607



RN 221531-77-7 USPATFULL


CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 221531-78-8 USPATFULL


CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 221531-79-9 USPATFULL


CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 221531-80-2 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)


10/731,607



● HCl


RN 221531-81-3 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-
[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 221531-82-4 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(2-
methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 221531-84-6 USPATFULL


CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(3-
methyl-1-oxobutyl)- (9CI) (CA INDEX NAME)



RN 221531-85-7 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(4-
methyl-1-oxopentyl)-, monohydrochloride (9CI) (CA INDEX NAME)


10/731,607



● HCl


RN 221531-86-8 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(1-pyrrolidinylsulfonyl)- (9CI) (CA INDEX NAME)



RN 221533-09-1 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(1-piperidinylsulfonyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2003:325141 USPATFULL

TITLE: 2-(Substituted-phenyl)amino-imidazoline derivatives

INVENTOR(S): Bley, Keith Roger, Mountain View, CA, UNITED STATES

Clark, Robin Douglas, Palo Alto, CA, UNITED STATES

Jahangir, Alam, San Jose, CA, UNITED STATES

Kowalczyk, Bruce Andrew, Redwood City, CA, UNITED STATES

Lopez-Tapia, Francisco Javier, Fremont, CA, UNITED STATES

Muehldorf, Alexander Victor, Sunnyvale, CA, UNITED STATES

O'Yang, Counde, Sunnyvale, CA, UNITED STATES

Sun, Thomas Weitao, Fremont, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003229123	A1	20031211
	US 6693200	B2	20040217
APPLICATION INFO.:	US 2003-425778	A1	20030429 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2002-159589, filed on 31 May 2002, GRANTED, Pat. No. US 6596876 Division of Ser. No. US 2000-666065, filed on 19 Sep 2000, GRANTED, Pat. No. US 6472536 Division of Ser. No. US 1998-137507, filed		

10/731,607

on 20 Aug 1998, GRANTED, Pat. No. US 6184242

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-89916P	19980619 (60)
	US 1998-88015P	19980604 (60)
	US 1997-57808P	19970904 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROCHE PALO ALTO LLC, 3431 HILLVIEW AVENUE, PALO ALTO, CA, 94304	
NUMBER OF CLAIMS:	65	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	3492	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	This invention relates to IP receptor antagonists selected from the group of compounds represented by Formula I: ##STR1##	

where:

R_{sup}.1 is a group represented by formula (A), (B) or (C); ##STR2##


d other substituents as defined in the specification, and their pharmaceutically acceptable ts or crystal forms thereof; and pharmaceutical compositions containing them; and methods their use as therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 221531-76-6P 221531-77-7P 221531-78-8P
221531-79-9P 221531-80-2P 221531-81-3P
221531-82-4P 221531-84-6P 221531-85-7P
221531-86-8P 221533-09-1P
(preparation of 2-[(arylmethyl)phenylamino]-2-imidazolines as prostaglandin IP receptor antagonists)

RN 221531-76-6 USPATFULL


CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 221531-77-7 USPATFULL

CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)


10/731,607



● HCl

RN 221531-78-8 USPATFULL


CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 221531-79-9 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 221531-80-2 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 221531-81-3 USPATFULL


10/731,607

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-
[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 221531-82-4 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(2-
methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 221531-84-6 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(3-
methyl-1-oxobutyl)- (9CI) (CA INDEX NAME)



RN 221531-85-7 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(4-
methyl-1-oxopentyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 221531-86-8 USPATFULL


CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(1-
pyrrolidinylsulfonyl)- (9CI) (CA INDEX NAME)

10/731,607



RN 221533-09-1 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(1-piperidinylsulfonyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 3 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2003:51697 USPATFULL

TITLE: 2-(substituted-phenyl)amino-imidazoline derivatives

INVENTOR(S): Bley, Keith Roger, Mountain View, CA, UNITED STATES

Clark, Robin Douglas, Palo Alto, CA, UNITED STATES

Jahangir, Alam, San Jose, CA, UNITED STATES

Kowalczyk, Bruce Andrew, Redwood City, CA, UNITED STATES

Lopez-Tapia, Francisco Javier, Fremont, CA, UNITED STATES

Muehldorf, Alexander Victor, Sunnyvale, CA, UNITED STATES

O'Yang, Counde, Sunnyvale, CA, UNITED STATES

Sun, Thomas Weitao, Fremont, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003036655	A1	20030220
	US 6596876	B2	20030722
APPLICATION INFO.:	US 2002-159589	A1	20020531 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-666065, filed on 19 Sep 2000, ABANDONED Division of Ser. No. US 1998-137507, filed on 20 Aug 1998, GRANTED, Pat. No. US 6184242		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-89916P	19980619 (60)
	US 1998-88015P	19980604 (60)
	US 1997-57808P	19970904 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROCHE BIOSCIENCE, 3401 HILLVIEW AVENUE, INTELLECTUAL PROPERTY LAW DEPT., MS A2-250, PALO ALTO, CA, 94304-9819	
NUMBER OF CLAIMS:	65	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	3417	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to IP receptor antagonists selected from the group of compounds represented by Formula I: ##STR1##

where:

R^{sup.1} is a group represented by formula (A), (B) or (C); ##STR2##

d other substituents as defined in the specification, and their pharmaceutically acceptable ts or crystal forms thereof; and pharmaceutical compositions containing them; and methods their use as therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 221531-76-6P 221531-77-7P 221531-78-8P

221531-79-9P 221531-80-2P 221531-81-3P


221531-82-4P 221531-84-6P 221531-85-7P

221531-86-8P 221533-09-1P

(preparation of 2-[(arylmethyl)phenylamino]-2-imidazolines as prostaglandin IP receptor antagonists)


RN 221531-76-6 USPATFULL

CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 221531-77-7 USPATFULL

CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 221531-78-8 USPATFULL

CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)


10/731,607



● HCl


RN 221531-79-9 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 221531-80-2 USPATFULL


CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 221531-81-3 USPATFULL


CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 221531-82-4 USPATFULL


CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

10/731,607




RN 221531-84-6 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(3-methyl-1-oxobutyl)- (9CI) (CA INDEX NAME)



RN 221531-85-7 USPATFULL


CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(4-methyl-1-oxopentyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 221531-86-8 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(1-pyrrolidinylsulfonyl)- (9CI) (CA INDEX NAME)



RN 221533-09-1 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(1-piperidinylsulfonyl)- (9CI) (CA INDEX NAME)



10/731,607

L6 ANSWER 4 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2002:283379 USPATFULL
TITLE: 2-(substituted-phenyl)amino-imidazoline derivatives
INVENTOR(S): Bley, Keith Roger, Mountain View, CA, United States
Clark, Robin Douglas, Palo Alto, CA, United States
Jahangir, Alam, San Jose, CA, United States
Kowalczyk, Bruce Andrew, Redwood City, CA, United States
Lopez-Tapia, Francisco Javier, Fremont, CA, United States
Muehldorf, Alexander Victor, Sunnyvale, CA, United States
O'Yang, Counde, Sunnyvale, CA, United States
Sun, Thomas Weitao, Fremont, CA, United States
PATENT ASSIGNEE(S): Syntex (U.S.A.) LLC, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6472536	B1	20021029
APPLICATION INFO.:	US 2000-666065		20000919 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-137507, filed on 20 Aug 1998, now patented, Pat. No. US 6184242		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-89916P	19980619 (60)
	US 1998-88015P	19980604 (60)
	US 1997-57808P	19970904 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Morris, Patricia L.	
LEGAL REPRESENTATIVE:	Kaku, Janet, Pfister, Gloria	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	3143	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to IP receptor antagonists selected from the group of compounds represented by Formula I: ##STR1##

where:


R.sup.1 is a group represented by formula (A), (B) or (C); ##STR2##

and other substituents as defined in the specification, and their pharmaceutically acceptable salts or crystal forms thereof; and pharmaceutical compositions containing them; and methods for their use as therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 221531-76-6P 221531-77-7P 221531-78-8P
221531-79-9P 221531-80-2P 221531-81-3P
221531-82-4P 221531-84-6P 221531-85-7P
221531-86-8P 221533-09-1P
(preparation of 2-[(arylmethyl)phenylamino]-2-imidazolines as prostaglandin IP receptor antagonists)
RN 221531-76-6 USPATFULL
CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

10/731,607



RN 221531-77-7 USPATFULL


CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 221531-78-8 USPATFULL


CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 221531-79-9 USPATFULL


CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 221531-80-2 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)


10/731,607



● HCl


RN 221531-81-3 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-
[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 221531-82-4 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(2-
methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 221531-84-6 USPATFULL


CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(3-
methyl-1-oxobutyl)- (9CI) (CA INDEX NAME)



RN 221531-85-7 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(4-
methyl-1-oxopentyl)-, monohydrochloride (9CI) (CA INDEX NAME)


10/731,607



● HCl


RN 221531-86-8 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(1-pyrrolidinylsulfonyl)- (9CI) (CA INDEX NAME)



RN 221533-09-1 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(1-piperidinylsulfonyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 5 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2001:18488 USPATFULL

TITLE: 2-(substituted-phenyl)amino-imidazoline derivatives

INVENTOR(S): Bley, Keith Roger, Mountain View, CA, United States

Clark, Robin Douglas, Palo Alto, CA, United States

Jahangir, Alam, San Jose, CA, United States

Kowalczyk, Bruce Andrew, Redwood City, CA, United States

Lopez-Tapia, Francisco Javier, Fremont, CA, United States

Muehldorf, Alexander Victor, Sunnyvale, CA, United States

O'Yang, Counde, Sunnyvale, CA, United States

Sun, Thomas Weitao, Fremont, CA, United States

PATENT ASSIGNEE(S): Syntex USA (LLC), Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6184242	B1	20010206
APPLICATION INFO.:	US 1998-137507		19980820 (9)

NUMBER	DATE
-----	-----

10/731,607

PRIORITY INFORMATION: US 1998-89916P 19980619 (60)
US 1998-88015P 19980604 (60)
US 1997-57808P 19970904 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Morris, Patricia L.
LEGAL REPRESENTATIVE: Kaku, Janet, Pfister, GloriaBurns, Doane, Swecker & Mathis LLP
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 3210

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to IP receptor antagonists selected from the group of compounds represented by Formula I: ##STR1##

where:

R.sup.1 is a group represented by formula (A), (B) or (C); ##STR2##

and other substituents as defined in the specification, and their pharmaceutically acceptable salts or crystal forms thereof; and pharmaceutical compositions containing them; and methods for their use as therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 221531-76-6P 221531-77-7P 221531-78-8P

221531-79-9P 221531-80-2P 221531-81-3P


221531-82-4P 221531-84-6P 221531-85-7P

221531-86-8P 221533-09-1P

(preparation of 2-[(arylmethyl)phenylamino]-2-imidazolines as prostaglandin IP receptor antagonists)


RN 221531-76-6 USPATFULL

CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 221531-77-7 USPATFULL


CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



10/731,607

RN 221531-78-8 USPATFULL


CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl)methyl]-N-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 221531-79-9 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl)methyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 221531-80-2 USPATFULL


CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl)methyl]-1-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 221531-81-3 USPATFULL


CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl)methyl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)



10/731,607


RN 221531-82-4 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 221531-84-6 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(3-methyl-1-oxobutyl)- (9CI) (CA INDEX NAME)



RN 221531-85-7 USPATFULL


CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(4-methyl-1-oxopentyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 221531-86-8 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(1-pyrrolidinylsulfonyl)- (9CI) (CA INDEX NAME)



RN 221533-09-1 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(1-piperidinylsulfonyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 6 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2000:6930 USPATFULL

TITLE: Integrally formed suture and suture lock

INVENTOR(S): Pagedas, Anthony C., 8401 W. Edgerton, Greendale, WI,
United States 53129

PATENT ASSIGNEE(S): Pagedas, Anthony C., United States (U.S. individual)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6015428		20000118
APPLICATION INFO.:	US 1998-89916		19980603 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-48489P	19970603 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Buiz, Michael	
ASSISTANT EXAMINER:	Ho, (Jackie) Tan-Uyen T.	
LEGAL REPRESENTATIVE:	Ryan Kromholz & Manion, S.C.	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 12 Drawing Page(s)	
LINE COUNT:	449	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A molded plastic one-piece self adjusting self locking suture lock to be used with surgical suture thread and suture needle, said self adjusting self locking suture lock comprising: a body having a front side, a back side, a first edge, a thread retaining opening, and a stitch lock opening; the thread retaining opening having a thread opening slightly smaller in diameter than said suture thread and a slot extending outwardly from said thread opening to said first edge. The stitch lock opening being right cylindrical and having an outer edge on said front side. The body having a plurality of integral tongues connected to said outer edge of the stitch lock opening near said front side and extending diametrically inward at an angle from said front side toward said back side. The tongues being of sufficient dimension and number to occupy substantially the entire circumference of the outer edge. Each of said tongues having a conical sectional shape such that the plurality of tongues connected near the outer edge of the front side form a conical structure having an approach opening on this front side larger than an exit opening on the back side.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 221531-76-6P 221531-77-7P 221531-78-8P

221531-79-9P 221531-80-2P 221531-81-3P

221531-82-4P 221531-84-6P 221531-85-7P


221531-86-8P 221533-09-1P

(preparation of 2-[(arylmethyl)phenylamino]-2-imidazolines as prostaglandin IP receptor antagonists)

RN 221531-76-6 USPATFULL


CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

10/731,607



RN 221531-77-7 USPATFULL


CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 221531-78-8 USPATFULL


CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 221531-79-9 USPATFULL


CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 221531-80-2 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)


10/731,607



● HCl


RN 221531-81-3 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 221531-82-4 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 221531-84-6 USPATFULL


CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(3-methyl-1-oxobutyl)- (9CI) (CA INDEX NAME)



RN 221531-85-7 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(4-methyl-1-oxopentyl)-, monohydrochloride (9CI) (CA INDEX NAME)


10/731,607



● HCl


RN 221531-86-8 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(1-pyrrolidinylsulfonyl)- (9CI) (CA INDEX NAME)



RN 221533-09-1 USPATFULL

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(1-piperidinylsulfonyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 7 OF 8 USPAT2 on STN

ACCESSION NUMBER: 2003:325141 USPAT2

TITLE: 2-(substituted-phenyl)amino-imidazoline derivatives

INVENTOR(S): Bley, Keith Roger, Mountain View, CA, United States

Clark, Robin Douglas, Palo Alto, CA, United States

Jahangir, Alam, San Jose, CA, United States

Kowalczyk, Bruce Andrew, Redwood City, CA, United States

Lopez-Tapia, Francisco Javier, Fremont, CA, United States

Muehldorf, Alexander Victor, Sunnyvale, CA, United States

O'Yang, Counde, Sunnyvale, CA, United States

Sun, Thomas Weitao, Fremont, CA, United States

PATENT ASSIGNEE(S): Syntex (U.S.A.) LLC, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6693200	B2	20040217
APPLICATION INFO.:	US 2003-425778		20030429 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2002-159589, filed on 31 May 2002, now patented, Pat. No. US 6596876 Division of Ser. No. US 2000-666065, filed on 19 Sep 2000, now		

patented, Pat. No. US 6472536 Division of Ser. No. US 1998-137507, filed on 20 Aug 1998, now patented, Pat. No. US 6184242

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-89916P	19980619 (60)
	US 1998-88015P	19980604 (60)
	US 1997-57808P	19970904 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Morris, Patricia L.	
LEGAL REPRESENTATIVE:	Hall, Robert C., Pfister, Gloria, Pories, Rohan	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	3130	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to IP receptor antagonists selected from the group of compounds represented by Formula I: ##STR1##

where:

R^{sup.1} is a group represented by formula (A), (B) or (C); ##STR2##

and other substituents as defined in the specification, and their pharmaceutically acceptable salts or crystal forms thereof; and pharmaceutical compositions containing them; and methods for their use as therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 221531-76-6P 221531-77-7P 221531-78-8P

221531-79-9P 221531-80-2P 221531-81-3P


221531-82-4P 221531-84-6P 221531-85-7P

221531-86-8P 221533-09-1P

(preparation of 2-[(arylmethyl)phenylamino]-2-imidazolines as prostaglandin IP receptor antagonists)

RN 221531-76-6 USPAT2


CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 221531-77-7 USPAT2

CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)


10/731,607



● HCl

RN 221531-78-8 USPAT2


CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 221531-79-9 USPAT2

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 221531-80-2 USPAT2

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 221531-81-3 USPAT2


10/731,607

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-
[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 221531-82-4 USPAT2

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(2-
methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 221531-84-6 USPAT2

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(3-
methyl-1-oxobutyl)- (9CI) (CA INDEX NAME)



RN 221531-85-7 USPAT2

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(4-
methyl-1-oxopentyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 221531-86-8 USPAT2


CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(1-
pyrrolidinylsulfonyl)- (9CI) (CA INDEX NAME)

10/731,607



RN 221533-09-1 USPAT2

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(1-piperidinylsulfonyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 8 OF 8 USPAT2 on STN

ACCESSION NUMBER: 2003:51697 USPAT2

TITLE: 2-(substituted-phenyl)amino-imidazoline derivatives

INVENTOR(S): Bley, Keith Roger, Mountain View, CA, United States

Clark, Robin Douglas, Palo Alto, CA, United States

Jahangir, Alam, San Jose, CA, United States

Kowalczyk, Bruce Andrew, Redwood City, CA, United States

Lopez-Tapia, Francisco Javier, Fremont, CA, United States

Muehldorf, Alexander Victor, Sunnyvale, CA, United States

O'Yang, Counde, Sunnyvale, CA, United States

Sun, Thomas Weitao, Fremont, CA, United States

PATENT ASSIGNEE(S): Syntex (U.S.A.) LLC, Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6596876	B2	20030722
APPLICATION INFO.:	US 2002-159589		20020531 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-666065, filed on 19 Sep 2000, now patented, Pat. No. US 6472536 Division of Ser. No. US 1998-137507, filed on 20 Aug 1998, now patented, Pat. No. US 6184242		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-89916P	19980619 (60)
	US 1998-88015P	19980604 (60)
	US 1997-57808P	19970904 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Morris, Patricia L.

LEGAL REPRESENTATIVE: Peries, Rohan, Hall, Robert C.

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)

LINE COUNT: 3176

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to IP receptor antagonists selected from the

10/731,607

group of compounds represented by Formula I: ##STR1##

where:

R^{sup.1} is a group represented by formula (A), (B) or (C); ##STR2##

and other substituents as defined in the specification, and their pharmaceutically acceptable salts or crystal forms thereof; and pharmaceutical compositions containing them; and methods and their use as therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 221531-76-6P 221531-77-7P 221531-78-8P

221531-79-9P 221531-80-2P 221531-81-3P


221531-82-4P 221531-84-6P 221531-85-7P

221531-86-8P 221533-09-1P

(preparation of 2-[(arylmethyl)phenylamino]-2-imidazolines as prostaglandin IP receptor antagonists)


RN 221531-76-6 USPAT2

CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 221531-77-7 USPAT2

CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 221531-78-8 USPAT2

CN 1-Piperidinecarboxamide, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-N-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)


10/731,607



● HCl


RN 221531-79-9 USPAT2

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 221531-80-2 USPAT2


CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 221531-81-3 USPAT2


CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 221531-82-4 USPAT2


CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

10/731,607




RN 221531-84-6 USPAT2

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(3-methyl-1-oxobutyl)- (9CI) (CA INDEX NAME)



RN 221531-85-7 USPAT2


CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(4-methyl-1-oxopentyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 221531-86-8 USPAT2

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(1-pyrrolidinylsulfonyl)- (9CI) (CA INDEX NAME)



RN 221533-09-1 USPAT2

CN Piperidine, 4-[[4-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]methyl]-1-(1-piperidinylsulfonyl)- (9CI) (CA INDEX NAME)



10/731,607

=>